|Bid||9.36 x 4000|
|Ask||9.77 x 3200|
|Day's Range||9.36 - 9.53|
|52 Week Range||6.26 - 13.91|
|Beta (3Y Monthly)||2.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.67|
Sangamo (SGMO) delivered earnings and revenue surprises of 27.27% and 56.70%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will be featured in poster presentations at the 61st Annual Meeting of the American Society of Hematology (ASH). The SB-525 poster will show updated Alta study data including durability of Factor VIII (FVIII) levels, bleeding rate, factor usage, and safety, for all five patients in the high dose cohort of 3e13 vg/kg, with approximately 4 months to 11 months of follow-up after treatment with SB-525.
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31, 2019. Mr. Lee oversees finance, facilities and information technology functions for Sangamo and reports to the Chief Executive Officer. “I am excited to welcome Sung to the leadership team and believe that his exceptional track record of improving operational performance, leading large teams, and communicating with investors, as well as his deep experience and success in financial planning and analysis, will have a significant impact on Sangamo as we continue to grow,” said Sandy Macrae, Sangamo's Chief Executive Officer.
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
If you want to know who really controls Sangamo Therapeutics, Inc. (NASDAQ:SGMO), then you'll have to look at the...
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today the appointment of Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer. Dr. Cockroft will oversee all clinical development activities and operations and will report to the Executive Vice President of Research and Development. “Bettina brings over 20 years of clinical development experience, having worked across multiple therapeutic areas and leading programs in several countries,” said Adrian Woolfson, BM., B.Ch., Ph.D., Executive Vice President, Research and Development.
Sangamo Therapeutics, Inc. , a genomic medicine company, announced today that members of the management team will present at the following investor and industry confe
Sandy Macrae has been the CEO of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) since 2016. This analysis aims first to...
Sangamo (SGMO) delivered earnings and revenue surprises of 25.71% and -9.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.